XERIS BIOPHARMA HOLDINGS INC (XERS)

US98422E1038 - Common Stock

2.21  +0.17 (+8.33%)

After market: 2.2197 +0.01 (+0.44%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

XERIS BIOPHARMA HOLDINGS INC

NASDAQ:XERS (3/28/2024, 5:20:07 PM)

After market: 2.2197 +0.01 (+0.44%)

2.21

+0.17 (+8.33%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap310.39M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

XERS Daily chart

Company Profile

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The company is headquartered in Chicago, Illinois and currently employs 355 full-time employees. The company went IPO on 2018-06-21. The firm is focused on improving patients’ lives by developing and commercializing products across a range of therapies. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), and Levothyroxine (XP-8121). XP-8121, is an early-stage program designed to address maintenance therapy in patients with congenital or acquired hypothyroidism who require continuous thyroid hormone replacement.

Company Info

XERIS BIOPHARMA HOLDINGS INC

1375 West Fulton Street, Suite 1300

Chicago ILLINOIS 60601

P: 18444455704

CEO: Paul R. Edick

Employees: 355

Website: https://www.xerispharma.com/

XERS News

News Image22 days ago - InvestorPlaceXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023

XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

News Image22 days ago - BusinessInsiderXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xeris Biopharma Holdings (NASDAQ:XERS) just reported results for the fourth qua...

News Image22 days ago - Xeris Biopharma Holdings, Inc.Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
News Image22 days ago - Xeris Biopharma Holdings, Inc.Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
News Imagea month ago - Xeris Biopharma Holdings, Inc.Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
News Imagea month ago - Market News VideoInsiders Were Right: XERS Makes New 52-Week High

XERS Twits

Here you can normally see the latest stock twits on XERS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example